NCT05564377 2026-03-18
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
9 trialsNCT06494150 2026-02-23
Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)
University of Oklahoma
Phase 2 Recruiting
NCT05082025 2026-01-09
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT06630325 2026-01-07
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT05113368 2025-08-21
Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
Case Comprehensive Cancer Center
Phase 2 Recruiting
NCT03926936 2024-05-28
FUCHSia
University Hospital, Gasthuisberg
Phase 2 Completed
NCT00006903 2019-03-20
Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer
GOG Foundation
Phase 2 Unknown
NCT00617188 2017-12-28
Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00334295 2012-07-31
Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
AstraZeneca
Phase 2 Completed